EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Coagulation dynamics during coronary angiography in patients receiving chronic direct oral anticoagulants: insights from the randomized POPular MEASURE study

Ashley Verburg, Wilbert Bor, Magdolna Nagy, Henri Mh Spronk, Hugo Ten Cate, Christian Hackeng, Jur Ten Berg

Journal of Thrombosis and Haemostasis · 2026

DOI: 10.1016/j.jtha.2026.09.026 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Thrombosis and Haemostasis, 2026. Verfasst von Ashley Verburg und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands; Cardiovascular Research Institute Maastricht (CARIM), Maastricht Univer…. Hauptthemen laut MEDLINE: Coronary Angiography, Anticoagulants, Heparin, Blood Coagulation. Die Arbeit nennt 30 Literaturangaben. Gefördert von: Haemonetics Corporation, Netherlands Heart Foundation, St Antonius Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The role of peri-procedural unfractionated heparin (UFH) in patients receiving chronic direct oral anticoagulants (DOACs) undergoing coronary angiography (CAG) remains uncertain. OBJECTIVE: To investigate whether omission of UFH affects thrombin generation and coagulation dynamics. METHODS: In this prospective, randomized, mechanistic study, 120 patients undergoing elective CAG were included: 80 on chronic DOAC therapy randomized to UFH (DOAC + UFH, N = 39) or placebo (DOAC + placebo, N = 41), and a parallel reference cohort without oral anticoagulation receiving UFH (N = 40). Blood samples were collected at baseline, 30, 120, and 240 minutes after UFH administration. The primary endpoint was peak thrombin generation assessed using prothrombin fragment 1+2 (F1+2), with noninferiority of DOAC + placebo vs reference tested against a prespecified margin of 100 pmol/L. RESULTS: Peak F1+2 levels were lower in DOAC + placebo vs reference (165.5 vs 248.7 pmol/L; mean difference, -133.0 pmol/L), with the upper bound of the 1-sided 97.5% confidence interval (-36.4 pmol/L) below the noninferiority margin (P < .001). No difference was observed between DOAC + placebo and DOAC + UFH (165.5 vs 166.2 pmol/L; P = .93). Secondary markers were consistent: thrombin generation was lower in DOAC-treated patients vs reference, with no difference in fibrin formation or platelet activation. UFH prolonged clot initiation without affecting clot strength or fibrinolysis. CONCLUSIONS: In patients on chronic DOAC therapy undergoing CAG, omission of peri-procedural UFH was not associated with increased thrombin generation. DOAC therapy alone provided sustained suppression of coagulation activation, questioning the routine use of UFH in this setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Coronary AngiographyAnticoagulantsHeparinBlood CoagulationHumansFemaleAdministration, OralProspective StudiesMaleAgedThrombinPeptide FragmentsTime FactorsMiddle AgedProthrombinTreatment OutcomeBiomarkers

Stichwörter der Autor:innen

anticoagulantsblood coagulationcoronary angiographyheparinthrombin

Substanzen

AnticoagulantsHeparinThrombinPeptide Fragmentsprothrombin fragment 1.2ProthrombinBiomarkers

Autor:innen und Institutionen

  • Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands; Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands. Electronic address: as.verburg@anto…
  • Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands.
  • Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands; Department of Biochemistry, Maastricht University, Maastricht, The Netherlands; Thrombosis Expertise Center, Hear…
  • Department of Clinical Chemistry, St. Antonius Hospital, Nieuwegein, The Netherlands.
  • Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands; Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands; Department of Cardiology, Maastrich…

Förderung

  • Haemonetics Corporation
  • Netherlands Heart Foundation
  • St Antonius Hospital

Zitieren

APA

Verburg, A., Bor, W., Nagy, M., Spronk, H. M., Cate, H. T., Hackeng, C., & Berg, J. T. (2026). Coagulation dynamics during coronary angiography in patients receiving chronic direct oral anticoagulants: insights from the randomized POPular MEASURE study. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2026.09.026

Vancouver

Verburg A, Bor W, Nagy M, Spronk HM, Cate HT, Hackeng C, et al. Coagulation dynamics during coronary angiography in patients receiving chronic direct oral anticoagulants: insights from the randomized POPular MEASURE study. Journal of Thrombosis and Haemostasis. 2026. doi:10.1016/j.jtha.2026.09.026

BibTeX
@article{Verburg2026,
  author = {Verburg, Ashley and Bor, Wilbert and Nagy, Magdolna and Spronk, Henri Mh and Cate, Hugo Ten and Hackeng, Christian and Berg, Jur Ten},
  title = {Coagulation dynamics during coronary angiography in patients receiving chronic direct oral anticoagulants: insights from the randomized POPular MEASURE study},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2026},
  doi = {10.1016/j.jtha.2026.09.026}
}
Kostenlos starten →